Clinical Trial Update: A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC [Phase 2]

View source ↗

Summary

The document reports the completion of a Phase 2 clinical trial comparing BMS-690514 with erlotinib in patients with previously treated non-small cell lung canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BMS-690514
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED